Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gert J Ossenkoppele

Showing results (61-70 of 193) with videos related to

Pageof 20
Sort By:
Cancer Immunology, Immunotherapy : CII|April 12, 2003
Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisationIlse Houtenbos, Theresia M Westers, Anita G M Stam, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 2016
Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopeniasEline M P Cremers, Theresia M Westers, Canan Alhan, et al.
British Journal of Haematology|October 11, 2021
The wider perspective: twenty years of clinical trials in myelodysplastic syndromesCarolien Duetz, David G J Cucchi, Tobias B Polak, et al.
Leukemia|March 24, 2021
Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerationsRoland B Walter, Yishai Ofran, Agnieszka Wierzbowska, et al.
Haematologica|February 21, 2009
Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndromeMartine E D Chamuleau, Theresia M Westers, Linda van Dreunen, et al.
Stem Cells (Dayton, Ohio)|December 20, 2008
Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemiaBijan Moshaver, Anna van Rhenen, Angèle Kelder, et al.
European Journal of Haematology|August 15, 2019
Survival of early posthematopoietic stem cell transplantation relapse of myeloid malignanciesGreta de Jong, Jeroen J W M Janssen, Bart J Biemond, et al.
Blood|December 30, 2009
Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatmentTheresia M Westers, Canan Alhan, Martine E D Chamuleau, et al.
British Journal of Haematology|October 8, 2019
TP53 mutations and relevance of expression of TP53 pathway genes in paediatric acute myeloid leukaemiaDavid G J Cucchi, Costa Bachas, Kim Klein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2013
MicroRNA profiling can classify acute leukemias of ambiguous lineage as either acute myeloid leukemia or acute lymphoid leukemiaDavid C de Leeuw, Willemijn van den Ancker, Fedor Denkers, et al.
Pageof 20

Showing results (61-70 of 193) with videos related to

Sort By:
Pageof 20
Cancer Immunology, Immunotherapy : CII|April 12, 2003
Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisationIlse Houtenbos, Theresia M Westers, Anita G M Stam, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 2016
Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopeniasEline M P Cremers, Theresia M Westers, Canan Alhan, et al.
British Journal of Haematology|October 11, 2021
The wider perspective: twenty years of clinical trials in myelodysplastic syndromesCarolien Duetz, David G J Cucchi, Tobias B Polak, et al.
Leukemia|March 24, 2021
Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerationsRoland B Walter, Yishai Ofran, Agnieszka Wierzbowska, et al.
Haematologica|February 21, 2009
Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndromeMartine E D Chamuleau, Theresia M Westers, Linda van Dreunen, et al.
Stem Cells (Dayton, Ohio)|December 20, 2008
Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemiaBijan Moshaver, Anna van Rhenen, Angèle Kelder, et al.
European Journal of Haematology|August 15, 2019
Survival of early posthematopoietic stem cell transplantation relapse of myeloid malignanciesGreta de Jong, Jeroen J W M Janssen, Bart J Biemond, et al.
Blood|December 30, 2009
Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatmentTheresia M Westers, Canan Alhan, Martine E D Chamuleau, et al.
British Journal of Haematology|October 8, 2019
TP53 mutations and relevance of expression of TP53 pathway genes in paediatric acute myeloid leukaemiaDavid G J Cucchi, Costa Bachas, Kim Klein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2013
MicroRNA profiling can classify acute leukemias of ambiguous lineage as either acute myeloid leukemia or acute lymphoid leukemiaDavid C de Leeuw, Willemijn van den Ancker, Fedor Denkers, et al.
Pageof 20